Lavie Bio Overview
Lavie Bio aims to improve food quality, health, and agricultural sustainability through the introduction of microbiome-based agriculturalbiological products. Utilizing proprietary computational predictive technologies, Lavie Bio is developing biostimulants and biopesticides and is engaged in an ongoing collaboration with Corteva for the development of corn biostimulants. Lavie Bio is a subsidiary of Evogene Ltd.
Cumulative Funding Raised Over Time ($)
$27.0MAug 2019
$37.0MAug 2022
Latest News
growth-positive
Conference call and webcast: today, August 19, 2025, 9:00 am ET Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a...
Evogene Ltd. reported its financial results for the first half of 2025, highlighting a strategic shift towards AI-driven innovation with its ChemPass AI platform. The company completed the sale of Lavie Bios activities and the MicroBoost AI for Ag platform to ICL for $18.71 million, boosting its cash position. Evogene also raised $4.4 million through an at-the-market facility, reflecting strong market confidence. The company is focusing on enhancing ChemPass AI, expanding strategic collaborations in pharma, and integrating AgPlenus activities. Evogene executed a 30% workforce reduction to streamline operations and improve efficiency. The company is leveraging partnerships with Google Cloud and Tel Aviv University to advance its AI capabilities in pharmaceuticals and agriculture.
AcquisitionInvestmentLayoffsPartnersCustomers
growth-positive
/PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company utilizing cutting-edge artificial intelligence and predictive...
Evogene Ltd. announced the successful divestiture of its ag-biologicals subsidiary, Lavie Bio Ltd., to ICL Group Ltd. This transaction includes the transfer of Lavie Bios proprietary technology and personnel to ICL, along with Evogenes MicroBoost AI platform. The divestiture aligns with Evogenes strategy to unlock the value of its subsidiaries and technology. Lavie Bios existing partnerships remain intact, potentially generating future revenues. ICL aims to enhance its ag-biologicals market position by integrating Lavie Bios platform with its expertise. This strategic move is expected to advance sustainable agricultural solutions. Evogene continues to leverage AI technology across its subsidiaries for product development.
Acquired-byAcquisition
growth-positive
/PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product...
Evogene Ltd., a computational biology company, has entered into a definitive agreement with ICL to acquire the majority of its subsidiary, Lavie Bio Ltd. This acquisition includes Lavie Bios core team, BDD technology platform, microbial bank, data assets, and commercial products. Additionally, ICL will acquire Evogenes MicroBoost AI for AG platform. The transaction is expected to close in the second quarter of 2025. This strategic move follows more than two years of collaboration between ICL and Lavie Bio, focusing on developing bio-stimulant solutions for agriculture. The integration of Lavie Bios activities into ICL is anticipated to advance the global ag-biologicals field and drive innovation in agriculture.
Acquired-byPartners
growth-positive
/PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), announced receiving a grant from...
Lavie Bio Ltd., a subsidiary of Evogene Ltd., has received a grant from the Israel Innovation Authority to advance its MicroFermentor technology. This innovative technology aims to reduce application costs, extend shelf life, and enhance bacterial viability in agricultural applications. The grant supports the next phase of development towards commercialization, following successful initial experiments. The global ag-biologicals market is rapidly growing, driven by increasing demand for sustainable agricultural solutions. Lavie Bios technology could significantly impact the market by enabling the introduction of diverse bacterial-based products. The company plans to implement this technology in its product pipeline and with collaboration partners, potentially revolutionizing the ag-biologicals industry.
Investment
growth-positive
Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals
Lavie Bio Ltd., a subsidiary of Evogene Ltd., has received a grant from the Israel Innovation Authority to advance its MicroFermentor technology, which aims to enhance the delivery of ag-biologicals in agriculture. This innovative technology allows for the multiplication of beneficial bacteria directly on plants, reducing costs and extending shelf life. The grant will support the next phase of development towards commercialization. The global ag-biologicals market is growing rapidly, driven by increasing demand for sustainable agricultural practices. Lavie Bio plans to implement this technology in its product pipeline and introduce it to collaboration partners, potentially revolutionizing the ag-biologicals industry.
Investment
| Sector | Agriculture & Food Technologies |
Funding
| Total funding | $37M |
| Last funding | Undisclosed |
| Stage | Acquired |
| Rounds | 3 |
| Investors | 2 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | lavie-bio.com |
| Careers | Careers page |
Locations
Derech Gad Feinstein 13, Rehovot, Israel
3730 Foundry Way #218, St. Louis, MO 63110, USA
Photos & Videos
1 item(s)
Lavie Bio Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Climate TechFood & Land UseSustainable FarmingAgriculture & Food TechnologiesAg TechFarm Equipment & TreatmentGenetics & InputTarget Customer
Agriculture & FoodCropsCore Technology
BiologicalsMicroorganismsTags (10)
fungicidesclimate-techpesticidesbiotechnologyagtechmicrobiomeplasticsplant-protectioncropsagricultureGeographic Markets
United StatesGlobalCanadaLavie Bio Financials
$37M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
Acquired
Funding stage
3
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$27.0MAug 2019
$37.0MAug 2022
Private Equity Funding
Convertible Debt
Aug 2022
$10M
ICL Planet Startup Hub
A Round
Aug 2019
$27M
Corteva
Non-Equity Funding
GrantEvent
Sep 2024
Undisclosed
Israel Innovation Authority
Public Offering / Exit
MNAEvent
Apr 2025
Undisclosed
Lavie Bio Lifecycle
Cumulative Funding Raised Over Time
$27.0MAug 2019
$37.0MAug 2022
All Events
Convertible Debt
Aug 2022
$10M
ICL Planet Startup Hub
A Round
Aug 2019
$27M
Corteva
GrantEvent
Sep 2024
Undisclosed
Israel Innovation Authority
MNAEvent
Apr 2025
Undisclosed
Lavie Bio News
17 articles
growth-positive
Conference call and webcast: today, August 19, 2025, 9:00 am ET Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a...
Evogene Ltd. reported its financial results for the first half of 2025, highlighting a strategic shift towards AI-driven innovation with its ChemPass AI platform. The company completed the sale of Lavie Bios activities and the MicroBoost AI for Ag platform to ICL for $18.71 million, boosting its cash position. Evogene also raised $4.4 million through an at-the-market facility, reflecting strong market confidence. The company is focusing on enhancing ChemPass AI, expanding strategic collaborations in pharma, and integrating AgPlenus activities. Evogene executed a 30% workforce reduction to streamline operations and improve efficiency. The company is leveraging partnerships with Google Cloud and Tel Aviv University to advance its AI capabilities in pharmaceuticals and agriculture.
AcquisitionInvestmentLayoffsPartnersCustomers
growth-positive
/PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company utilizing cutting-edge artificial intelligence and predictive...
Evogene Ltd. announced the successful divestiture of its ag-biologicals subsidiary, Lavie Bio Ltd., to ICL Group Ltd. This transaction includes the transfer of Lavie Bios proprietary technology and personnel to ICL, along with Evogenes MicroBoost AI platform. The divestiture aligns with Evogenes strategy to unlock the value of its subsidiaries and technology. Lavie Bios existing partnerships remain intact, potentially generating future revenues. ICL aims to enhance its ag-biologicals market position by integrating Lavie Bios platform with its expertise. This strategic move is expected to advance sustainable agricultural solutions. Evogene continues to leverage AI technology across its subsidiaries for product development.
Acquired-byAcquisition
growth-positive
/PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product...
Evogene Ltd., a computational biology company, has entered into a definitive agreement with ICL to acquire the majority of its subsidiary, Lavie Bio Ltd. This acquisition includes Lavie Bios core team, BDD technology platform, microbial bank, data assets, and commercial products. Additionally, ICL will acquire Evogenes MicroBoost AI for AG platform. The transaction is expected to close in the second quarter of 2025. This strategic move follows more than two years of collaboration between ICL and Lavie Bio, focusing on developing bio-stimulant solutions for agriculture. The integration of Lavie Bios activities into ICL is anticipated to advance the global ag-biologicals field and drive innovation in agriculture.
Acquired-byPartners
growth-positive
/PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), announced receiving a grant from...
Lavie Bio Ltd., a subsidiary of Evogene Ltd., has received a grant from the Israel Innovation Authority to advance its MicroFermentor technology. This innovative technology aims to reduce application costs, extend shelf life, and enhance bacterial viability in agricultural applications. The grant supports the next phase of development towards commercialization, following successful initial experiments. The global ag-biologicals market is rapidly growing, driven by increasing demand for sustainable agricultural solutions. Lavie Bios technology could significantly impact the market by enabling the introduction of diverse bacterial-based products. The company plans to implement this technology in its product pipeline and with collaboration partners, potentially revolutionizing the ag-biologicals industry.
Investment
growth-positive
Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals
Lavie Bio Ltd., a subsidiary of Evogene Ltd., has received a grant from the Israel Innovation Authority to advance its MicroFermentor technology, which aims to enhance the delivery of ag-biologicals in agriculture. This innovative technology allows for the multiplication of beneficial bacteria directly on plants, reducing costs and extending shelf life. The grant will support the next phase of development towards commercialization. The global ag-biologicals market is growing rapidly, driven by increasing demand for sustainable agricultural practices. Lavie Bio plans to implement this technology in its product pipeline and introduce it to collaboration partners, potentially revolutionizing the ag-biologicals industry.
Investment
growth-positive
ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants
ICL, a global specialty minerals company, and Lavie Bio Ltd., a subsidiary of Evogene Ltd., have announced a significant milestone in their collaboration to develop bio-stimulant solutions for key row crops facing various abiotic stresses. Using AI, Lavie Bio has identified more than a dozen novel microbial candidates believed to have commercial viability as bio-stimulants for crops grown under extreme weather conditions. The collaboration aims to deliver tangible benefits to farmers, including a 5% to 10% increase in yield. The success of this collaboration paves the way for field trials in the U.S. and Brazil in the second half of 2024.
PartnersExpand
growth-positive
Lavie Bio Successfully Secures Second Half Advance Payment of $2.5M after Meeting Corteva's Licensing Agreement Requirements
Lavie Bio Ltd., a subsidiary of Evogene Ltd., has secured the second-half advance payment of $2.5 million from Corteva after meeting the licensing agreement requirements. This completes the $5 million advance payment outlined in the agreement signed in July 2023. The agreement grants Corteva exclusive rights to further develop and commercialize Lavie Bios leading bio-fungicide product candidates. Lavie Bio will also be eligible for additional future milestone payments and royalties from Cortevas expected future sales of these products.
CustomersPartners
growth-positive
Syngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-Insecticide
Syngenta Crop Protection and Lavie Bio Ltd., a subsidiary of Evogene Ltd., have announced a partnership to develop new biological insecticidal solutions. The collaboration will use Lavie Bios technology platform to identify and optimize bio-insecticide candidates, and Syngentas global research, development, and commercialization capabilities. The aim is to combat the increasing threat of insects to crop health, a problem that is predicted to worsen with global warming and rising resistance to available insecticides.
Partners
growth-positive
Lavie Bio Announces Licensing Agreement for Bio-Fungicides with Corteva Agriscience - Lavie Bio
On July 17, 2023, Lavie Bio Ltd., a subsidiary of Evogene Ltd., announced a licensing agreement with Corteva Inc., a leading ag innovation company. The agreement grants Corteva exclusive rights to further develop and commercialize Lavie Bio’s lead bio-fungicide product candidates targeting fruit rots and powdery mildew. These diseases have resulted in annual losses estimated at billions of dollars globally. The agreement is part of Lavie Bio’s strategy to cooperate with leading companies to allow its products to reach farmers worldwide.
Partners
growth-positive
Lavie Bio Advances its Novel Bio-fungicide Program and Applies to the U.S. EPA for Regulatory Approval
Lavie Bio Ltd., a subsidiary of Evogene Ltd., has submitted the registration package for its novel bio-fungicide, LAV.311, to the United States Environmental Protection Agency. LAV.311 targets fruit rots and powdery mildews, which cause significant yield loss and quality reduction in crops. The product has shown promising results in trials conducted in the US, Europe, and Israel. Lavie Bio aims to launch LAV.311 commercially in the 2024 growing season. The companys product pipeline, including bio-fungicides and bio-inoculants, demonstrates the potential for implementing sustainable farming practices. Lavie Bio utilizes a proprietary computational predictive platform for the development of ag-biological products. Evogene, the parent company of Lavie Bio, is a computational biology company focused on revolutionizing life-science based product development.
Investment
ICL and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulant Products
growth-positive
Lavie Bio Reports Advancement in its Bio-Fungicide Program for Fruit Rots
Lavie Bio, a subsidiary of Evogene Ltd., has announced advancement to the pre-commercialization development stage in its bio-fungicide program targeting fruit rot diseases. The company conducted vineyard trials in Europe and the U.S., with promising results for its bio-fungicide product candidates. Lavie Bio has prioritized one candidate, LAV.311, for final development and submission of a regulatory dossier in 2022. The target market for the bio-fungicide is expected to be in the U.S., particularly California, and may include grapes, tomatoes, and berries. The program has been supported by the Israeli Innovation Authority. Lavie Bio aims to launch its first bio-fungicide product in 2024. Corteva, Inc. holds approximately 28% in Lavie Bio.
InvestmentPartners
growth-positive
Lavie Bio and United Agronomy Announce Signing of Distribution Agreement for Lavie Bio's Inoculant Product
Lavie Bio, a subsidiary of Evogene Ltd., has entered into a distribution agreement with United Agronomy (UA) for the distribution of LAV.211, a Lavie developed inoculant. The agreement will initially focus on spring wheat in North Dakota, USA. LAV.211 is a microbial-based inoculant that improves plant performance and increases yield. The distribution agreement follows successful evaluations and testing of LAV.211 with UA and its partners. Lavie Bio aims to improve food quality, sustainability, and agriculture productivity through the introduction of microbiome-based ag-biological products.
Partners
growth-positive
Lavie Bio Provides Product Pipeline Update for 2020
Lavie Bio, a subsidiary of Evogene Ltd., has provided an update on advancements achieved in its pipeline in 2020. The company is focusing on developing microbiome-based ag-biological products, including bio-stimulants and bio-pesticides, to improve food quality, sustainability, and agriculture productivity. The update includes the phase advancement of bio-stimulant LAV211, which is expected to be commercially launched in 2022. Lavie Bio also announced progress in its bio-fungicides and bio-insecticides pipelines, targeting various diseases and pests in crops. The companys sustainable approach to ag-biologicals holds promise for the future of agriculture. Lavie Bio utilizes the Biology Driven Design (BDD) platform, powered by Evogenes MicroBoost AI engine, for product discovery and development. Corteva, Inc. holds approximately 28% in Lavie Bio.
InvestmentPartners
growth-positive
Lavie Bio Announces Advancement in Its Product Development Pipeline for Wheat Bio-stimulants
Lavie Bio, a subsidiary of Evogene, announces phase advancement in its product development pipeline for wheat bio-stimulants. The leading candidate, LAV211, has shown consistent positive results in trials, with significant yield improvement compared to controls. Lavie Bio aims to commercialize the product by 2022. The global wheat flour market is expected to grow to $270 billion by 2022. Lavie Bios wheat bio-stimulant products have the potential to increase farmers profits by $20-$50 per acre. The next steps for Lavie Bio include continuing the development of scale-up production and application protocols, as well as testing improvements in broader field trials during the next crop season in North America.
CustomersInvestment
growth-positive
Corteva invests $10m in Evogene's LaVie Bio unit
Israeli agro-tech company Evogene Ltd. has signed a strategic cooperation agreement with Corteva Agriscience. Under the agreement, Corteva will invest $10 million in Evogenes subsidiary, LaVie Bio, which specializes in microbiome for improving plants. Corteva will hold 30% of LaVie Bio and have the right to market some of the products developed by the subsidiary. This investment supports Evogenes strategy of splitting off its activity into subsidiaries and allowing separate investments in each of them. The deal values LaVie Bio at tens of millions of dollars. LaVie Bio aims to improve food quality, agricultural sustainability, and crop yields through the use of microbiome products.
Partners
growth-positive
Evogene Announces Establishment of Ag-Biologicals Subsidiary - LaVie Bio Ltd.
Evogene Ltd. has announced the establishment of a new subsidiary, LaVie Bio Ltd, which will focus on improving food quality, agriculture sustainability, and productivity through the introduction of novel microbiome-based ag-biological products. The assets and capabilities of Evogenes Ag-Biologicals division, including a substantial pipeline of bio-stimulant and bio-pesticide product programs, will be transferred to LaVie. The new subsidiary will also have access to Evogenes Computational Predictive Biology (CPB) platform. The senior management of LaVie consists of the previous division managers, with Ido Dor appointed as CEO. This move is part of Evogenes strategy to establish focused subsidiaries in different market areas, with access to the CPB platform and the ability to pursue their own business strategies.
PartnersManagement Changes
Lavie Bio Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 39 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 15 classification IDs that could be used for matching.
Lavie Bio Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 515964708 |
| Crunchbase | lavie-bio |
| Phone | +97289311900 |
| Creator | Hilla Gorokhovsky |
| Creator email | hilla.gorokhovsky@sncentral.org |
| Last updater | Ortal Wein |
| Updater email | ortalw@sncentral.org |
| Last update | 2023-08-01T00:00:00.000Z |
| Created | 2019-02-27T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Acquired by ICL on Apr, 2025 |